EDIT:NASDAQ, Editas Medicine, Inc.

Why EDIT stock rose on October 28

Editas Medicine, Inc. rose 13.5% on Wednesday, October 28, 2026, on 4,427,600 shares. The headline around the move:

Oct 28: What Would Slower New Drug Sales Do To Vertex Stock?

EDIT stock overview

Editas Medicine, Inc. (EDIT:NASDAQ) closed at $2.61 on November 3, 2026, up 1.56% on the day. The stock trades 33.8% below its 52-week high of $3.94 and 57.2% above its 52-week low of $1.66. Over the past year, it lost 16.0%. Editas Medicine, Inc. is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).

Key figures

Price: $2.61
Day change: +1.56%
Volume: 917,908
Average volume: 2,694,303
Market cap: 400M+
52-week range: $1.66 – $3.94
50-day average: $2.75
200-day average: $2.68

Price action over the past year

In 252 trading sessions since October 31, 2025, EDIT closed higher on 115 days (46%). Its best day was March 9, 2026 (+16.00%) and its worst was June 2, 2026 (-15.57%). The stock moved 10% or more in a single session 17 times. It opened at least 5% above the previous day's high 1 time.

Recent signals

Oct 8, 2026: News catalyst: Biotech (News Catalysts scanner)
Aug 26, 2026: Spiked to $3.52 on 2M+ shares (Spikes scanner)

EDIT news

Oct 29, 2026: Global Gene Writing Technology Market Report 2026: Size, Trends, and Forecast to 2030 | Capitalize on 24.8% CAGR with Beam, Twist Bioscience, Tessera, and Intellia
Oct 28, 2026: What Would Slower New Drug Sales Do To Vertex Stock?
Oct 23, 2026: Vertex Stock Looks Expensive. Does It Get Cheaper Ahead?
Oct 21, 2026: Why Should You Think About Vertex Differently Now?
Oct 14, 2026: Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference
Oct 9, 2026: Is Vertex Stock Worth More Than Its Competitors?
Oct 9, 2026: EDIT Set to Begin First-in-Human Study in Hypercholesterolemia
Oct 8, 2026: Sector Update: Healthcare Stocks Softer Late Afternoon

About Editas Medicine, Inc.

Editas Medicine Inc is a genome editing company which is engaged in treating patients with genetically defined diseases by correcting disease-causing genes.

Similar stocks

Find more stocks like EDIT with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.